Markus Raderer (M Raderer)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 31

Top Topics

Randomized Controlled Trial

Top Venues

Therapeutic advances in medical oncology

Endocrine-related cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Marianne Pavel, Harald Lahner, Dieter Hörsch, Anja Rinke, Timm Denecke, Arend Koch, Benjamin Regnault, Dorit Helbig, Philipp Hoffmanns, Markus Raderer
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. The oncologist 29 (5) (2024)
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Elisabeth Kretschmer-Chott, Markus Raderer, Barbara Kiesewetter
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms. Therapeutic advances in medical oncology 16 (2024)
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Petar Popov, Elisabeth Kretschmer-Chott, Alexander Haug, Marius E Mayerhoefer, Markus Raderer, Barbara Kiesewetter
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms. Endocrine-related cancer 31 (3) (2024)
Eric Baudin, J Capdevila, D Hörsch, S Singh, M E Caplin, E M Wolin, W Buikhuisen, Markus Raderer, E Dansin, C Grohe, D Ferone, A Houchard, X-M Truong-Thanh, D Reidy-Lagunes
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study. Endocrine-related cancer 31 (9) (2024)
Eric Baudin, J Capdevila, D Hörsch, S Singh, M E Caplin, E M Wolin, W Buikhuisen, Markus Raderer, E Dansin, C Grohe, D Ferone, A Houchard, X-M Truong-Thanh, D Reidy-Lagunes
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study. Endocrine-related cancer 31 (9) (2024)
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Elisabeth Kretschmer-Chott, Markus Raderer, Barbara Kiesewetter
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms. Therapeutic advances in medical oncology 16 (2024)
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Petar Popov, Elisabeth Kretschmer-Chott, Alexander Haug, Marius E Mayerhoefer, Markus Raderer, Barbara Kiesewetter
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms. Endocrine-related cancer 31 (3) (2024)
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Petar Popov, Elisabeth Kretschmer-Chott, Alexander Haug, Marius E Mayerhoefer, Markus Raderer, Barbara Kiesewetter
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms. Endocrine-related cancer 31 (3) (2024)
Marianne Pavel, Harald Lahner, Dieter Hörsch, Anja Rinke, Timm Denecke, Arend Koch, Benjamin Regnault, Dorit Helbig, Philipp Hoffmanns, Markus Raderer
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. The oncologist (2024)
Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Elisabeth Kretschmer-Chott, Markus Raderer, Barbara Kiesewetter
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms. Therapeutic advances in medical oncology 16 (2024)
Marianne Pavel, Harald Lahner, Dieter Hörsch, Anja Rinke, Timm Denecke, Arend Koch, Benjamin Regnault, Dorit Helbig, Philipp Hoffmanns, Markus Raderer
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. The oncologist 29 (5) (2024)
Marianne Pavel, Harald Lahner, Dieter Hörsch, Anja Rinke, Timm Denecke, Arend Koch, Benjamin Regnault, Dorit Helbig, Philipp Hoffmanns, Markus Raderer
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. The oncologist 29 (5) (2024)
Eric Baudin, J Capdevila, D Hörsch, S Singh, M E Caplin, E M Wolin, W Buikhuisen, Markus Raderer, E Dansin, C Grohe, D Ferone, A Houchard, X-M Truong-Thanh, D Reidy-Lagunes
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study. Endocrine-related cancer 31 (9) (2024)
Eric Baudin, J Capdevila, D Hörsch, S Singh, M E Caplin, E M Wolin, W Buikhuisen, Markus Raderer, E Dansin, C Grohe, D Ferone, A Houchard, X-M Truong-Thanh, D Reidy-Lagunes
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study. Endocrine-related cancer 31 (9) (2024)
Marianne Pavel, Harald Lahner, Dieter Hörsch, Anja Rinke, Timm Denecke, Arend Koch, Benjamin Regnault, Dorit Helbig, Philipp Hoffmanns, Markus Raderer
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. The oncologist 29 (5) (2024)
Petar Popov, Ariane Steindl, Ladislaia Wolff, Elisabeth S Bergen, Franziska Eckert, Josa Maria Frischer, Georg Widhalm, Thorsten Fuereder, Markus Raderer, Anna Sophie Berghoff, Matthias Preusser, Barbara Kiesewetter
Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care center. Clinical & experimental metastasis (2023)
Markus Raderer, Barbara Kiesewetter, Ming-Qing Du
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal. Therapeutic advances in medical oncology 15 (2023)
Markus Raderer, Barbara Kiesewetter, Ming-Qing Du
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal. Therapeutic advances in medical oncology 15 (2023)
Markus Raderer, Barbara Kiesewetter, Ming-Qing Du
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal. Therapeutic advances in medical oncology 15 (2023)
Philipp Melhorn, Elisabeth Kretschmer-Chott, Ladislaia Wolff, Alexander Haug, Peter Mazal, Markus Raderer, Barbara Kiesewetter
Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna. Therapeutic advances in medical oncology 14 (2022)
Xia Lu, Raffaella Calabretta, Wolfgang Wadsak, Alexander R Haug, Marius E Mayerhoefer, Markus Raderer, Xiaoli Zhang, Jingle Li, Marcus Hacker, Xiang Li
Imaging Inflammation in Atherosclerosis with CXCR4-Directed [ 68 Ga]PentixaFor PET/MRI-Compared with [ 18 F]FDG PET/MRI. Life (Basel, Switzerland) 12 (7) (2022)
Markus Raderer, Barbara Kiesewetter
What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments. Therapeutic advances in medical oncology 13 (2021)
Barbara Kiesewetter, Philipp Riss, Christian Scheuba, Peter Mazal, Elisabeth Kretschmer-Chott, Alexander Haug, Markus Raderer
Management of adrenocortical carcinoma: are we making progress? Therapeutic advances in medical oncology 13 (2021)
Barbara Kiesewetter, Christiane Copie-Bergman, Michael Levy, Fangtian Wu, Jehan Dupuis, Caroline Barau, Luca Arcaini, Marco Paulli, Marco Lucioni, Arturo Bonometti, Antonio Salar-Silvestre, Maria Concepción Fernández-Rodríguez, Miguel Angel Piris, Francesco Cucco, Rachel Dobson, Yan Li, Zi Chen, Cyrielle Robe, Ingrid Simonitsch-Klupp, Andrew Wotherspoon, Markus Raderer, Ming Qing Du
Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers 13 (12) (2021)
Jaume Capdevila, Nicola Fazio, Carlos Lopez, Alexandre Teulé, Juan W Valle, Salvatore Tafuto, Ana Custodio, Nicholas Reed, Markus Raderer, Enrique Grande, Rocio Garcia-Carbonero, Paula Jiménez-Fonseca, Jorge Hernando, Alberto Bongiovanni, Francesca Spada, Vicente Alonso, Lorenzo Antonuzzo, Andrea Spallanzani, Alfredo Berruti, Adelaida La Casta, Isabel Sevilla, Patrizia Kump, Dario Giuffrida, Xavier Merino, Lorena Trejo, Pablo Gajate, Ignacio Matos, Angela Lamarca, Toni Ibrahim
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (20) (2021)
Fangtian Wu, Natsuko Watanabe, Maria-Myrsini Tzioni, Ayse U Akarca, Chunye Zhang, Yan Li, Zi Chen, Francesco Cucco, Natasha Carmell, Jaeduk Yoshimura Noh, Koichi Ito, Rachel Dobson, Sarah Moody, Wenqing Yao, Wenyan Zhang, Weiping Liu, Hongxiang Liu, Jessica Okosun, Andreas Chott, Yingwen Bi, Shih-Sung Chuang, Markus Raderer, Jian-Yong Li, Teresa Marafioti, Ming-Qing Du
Thyroid MALT lymphoma: self-harm to gain potential T-cell help. Leukemia 35 (12) (2021)
Antonia Pokorny, Barbara Kiesewetter, Markus Raderer
Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) outside of clinical trials: Real-world data from the University of Vienna. Hematological oncology 38 (3) (2020)
Barbara Kiesewetter, Ingrid Simonitsch-Klupp, Marius E Mayerhoefer, Werner Dolak, Julius Lukas, Markus Raderer
First Line Systemic Treatment for MALT Lymphoma-Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna. Cancers 12 (12) (2020)
Barbara Kiesewetter, Markus Raderer
Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). Hematological oncology 38 (4) (2020)
Gundula Rendl, B Sipos, A Becherer, S Sorko, Christian Trummer, Markus Raderer, Wolfgang Hitzl, M Ardelt, H J Gallowitsch, Christian Pirich
Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria. International journal of endocrinology 2020 (2020)
Noemi Pavo, Henrike Arfsten, Anna Cho, Georg Goliasch, Philipp E Bartko, Raphael Wurm, Claudia Freitag, Heinz Gisslinger, Gabriela Kornek, Guido Strunk, Markus Raderer, Christoph Zielinski, Martin Hülsmann
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients. Scientific reports 9 (1) (2019)